Page 1206 - Hematology_ Basic Principles and Practice ( PDFDrive )

1054 Part VII Hematologic Malignancies

leukemia with the Programa Espanol de Tratamiento en Hematologia Kenkre VP, Stock W: Burkitt lymphoma/leukemia: improving prognosis. Clin
pediatric-based protocol ALL-96. J Clin Oncol 26:1843, 2008. Lymphoma Myeloma 9:S231, 2009.
Stock W, La M, Sanford B, et al: What determines the outcomes for ado- Rizzieri D, Johnson J, Byrd J, et al: improved efficacy using rituximab and
lescents and young adults with acute lymphoblastic leukemia treated on brief duration, high intensity chemotherapy with filgrastim support for
cooperative group protocols? A comparison of Children’s Cancer Group Burkitt or aggressive lymphomas: cancer and Leukemia Group B study
and Cancer and Leukemia Group B studies. Blood 112:1646, 2008. 10 002. Br J Haematol 165:102, 2014.
Thomas DA, Cortes J, O’Brien S, et al: Hyper-CVAD program in Burkitt’s-
type adult acute lymphoblastic leukemia. J Clin Oncol 17:2461, 1999.
+
PH ALL
Cortes JE, Kim DW, Pinilla-Ibarz J, et al: A phase 2 trial of ponatinib in RELAPSED DISEASE AND NOVEL THERAPIES
Philadelphia chromosome positive leukemias. N Engl J Med 369:1783,
2013. Collins-Underwood J, Mullighan C: Genomic profiling of high risk acute
Foa R, Vitale A, Vignetti M, et al: Dasatinib as first-line treatment for adult lymphoblastic leukemia. Leukemia 24:1676–1685, 2010.
patients with Philadelphia chromosome-positive acute lymphoblastic DeAngelo DJ, Yu D, Johnson JL, et al: Nelarabine induces complete remis-
leukemia. Blood 118:6521, 2011. sions in adults with relapsed or refractory T-lineage acute lymphoblastic
Ravandi F, O’Brien S, Thomas D, et al: First report of phase 2 study of leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B
dasatinib with hyper-CVAD for the frontline treatment of patients with study 19801. Blood 109:5136, 2007.
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Kantarjian H, Thomas D, Jorgensen J, et al: Inotuzumab ozogamicin, an
Blood 116:2070, 2010. anti-CD22-calecheamicin conjugate, for refractory and relapsed acute
Thomas DA, Faderl S, Cortes J, et al: Treatment of Philadelphia chromosome- lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13:403, 2012.
positive acute lymphocytic leukemia with hyper-CVAD and imatinib Maude S, Frey N, Shaw P, et al: Chimeric antigen receptor T cells for
mesylate. Blood 103:4396, 2004. sustained remissions in leukemia. N Engl J Med 371:1507, 2014.
Vignetti M, Fazi P, Cimino G, et al: Imatinib plus steroids induces complete O’Brien S, Schiller G, Lister J, et al: High-dose vincristine sulfate lipo-
remissions and prolonged survival in elderly Philadelphia chromosome- some injection for advanced, relapsed, and refractory adult Philadelphia
positive patients with acute lymphoblastic leukemia without additional chromosome–negative acute lymphoblastic leukemia. J Clin Oncol
chemotherapy: results of the Gruppo Italiano Malattie Ematologiche 31:676, 2013.
dell’Adulto (GIMEMA) LAL0201-B protocol. Blood 109:3676, Park J, Riviere I, Wang X, et al: CD19-targeted 19-28z CAR modified
2007. autologous T cells induce high rates of complete remission and durable
Wetzler M, Watson D, Stock W, et al: Autologous transplantation for Phila- responses in adult patients with relapsed, refractory B-cell ALL. Blood
delphia chromosome positive acute lymphoblastic leukemia achieves out- 124(21):Abstract 382, 2014.
comes similar to allogeneic stem cell transplantation: Results of CALGB Roberts KG, Mullighan CG: Genomics in acute lymphoblastic leukaemia:
Study 10001 (Alliance). Haematologica 99:111, 2014. insights and treatment implications. Nat Rev Clin Oncol 12:344, 2015.
Yanada M, Takeuchi J, Sugiura I, et al: High complete remission rate and Topp MS, Gökbuget N, Stein AS, et al: Safety and activity of blinatumomab
promising outcome by combination of imatinib and chemotherapy for for adult patients with relapsed or refractory B-precursor acute lympho-
newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a blastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol
phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 16:57, 2014.
24:460, 2006. Weng AP, Ferrando AA, Lee W, et al: Activating mutations of NOTCH1
in human T cell acute lymphoblastic leukemia. Science 306:269, 2004.
BURKITT LYMPHOMA/LEUKEMIA
REFERENCES
Dunleavy K, Pittaluga S, Shovlin M, et al: Low-intensity therapy in adults
with Burkitt’s lymphoma. N Engl J Med 369:1915, 2013. For the complete list of references, log on to www.expertconsult.com.